The Mycobacterium Tuberculosis Structural Proteomics Project (XMTB) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
aims to contribute to combat
of one of most wide-spread and most lethal infectious diseases world-wide,
tuberculosis.The initiative is funded by the German Ministry for Science and Education and it
is coordinated by EMBL-Hamburg. It comprises four academic
partners and three industrial partners in Germany.
The overall
goal of the XMTB-Structural Proteomics
Consortium is to identify lead compounds against XMTB targets
for drug discovery, using a structure based approach. The XMTB targets are
selected by proteomics/transcriptomics oriented analyses of the MTB genome
and those of related mycobacteria. The molecular structures of these
targets are determined by X-ray crystallography. Small molecular ligands
are identified and structurally mapped by a range of biophysical and
NMR-based screening methods. Putative lead compounds are characterised and
validated byin vivoscreening methods.
The XMTB consortium cooperates with
International partners, particularly with the American
Mycobacterium Tuberculosis Structural Genomics
Consortium.
Up to December 2005
our consortium has deposited into RCSB Protein Data
Bank the following structures:
The XMTB consortium
performed number of automated screens
for novel small molecule antagonist of Mycobacterium
Tuberculosis. The following table
summarize our results.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||